Division of Vascular Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Division of Vascular Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Ann Vasc Surg. 2022 Nov;87:411-421. doi: 10.1016/j.avsg.2022.05.020. Epub 2022 Jun 3.
Infected abdominal aortic and/or iliac aneurysm (AAIA) is a rare condition with a high mortality rate when treated with open surgery. In the past decade, the condition has increasingly been treated with endovascular aneurysm repair (EVAR). However, early and late outcomes, including the continued need for antibiotic treatments and predictors of persistent infection, are poorly understood.
We evaluated the outcomes of patients who underwent EVAR for infected AAIA from January 2010 to October 2017. We collected data including patient age, gender, clinical presentation, aneurysm location, culture results, intraoperative details, postoperative complications, 30-day mortality, in-hospital mortality, persistent infection, reintervention, and survival.
Among 792 patients diagnosed with AAIA, 64 were diagnosed with primary infected aneurysm, underwent EVAR, and were included in this study (81.3% male; median age, 72 years; range, 18-94 years). The most commonly isolated organisms were Salmonella species (34%), followed by Streptococcus (21%), and Staphylococcus species (21%). Aneurysms were intact in 48 patients (75%) and were ruptured in 16 (25%). The perioperative mortality was 4.7% (3 patients) of whom one was diagnosed with ruptured infected AAIA. Six (9.4%) patients died during hospitalization, 5 of severe sepsis with multiorgan failure and one of myocardial infarction. Among the 58 surviving patients, 34 (58.6%) had persistent infection, of whom 13 (22.4%) required early and late reintervention, including 2 with endograft infection, 8 with primary and secondary aortoenteric fistula, 2 with recurrent new aortic infection, and one with graft limb occlusion. The remaining 24 patients were able to discontinue antibiotics and had no recurrence or need for reintervention. Overall survival rates at 1, 3, and 5 years in the antibiotic-discontinuation group were 91.7%, 87.5%, and 68.0%, respectively, and 82.4%, 52.6%, and 32.9%, respectively, in the persistent-infection group (P = 0.009). In multivariable analysis, primary aortoenteric fistula (Adjusted OR [aOR], 20.469; 95% confidence interval (CI), 1.265-331.320; P = 0.034) and preoperative serum albumin level <3 g/dL (aOR, 7.399; 95% CI, 1.176-46.558; P = 0.033) were preoperative parameter that predicted persistent infection. A C-reactive protein level more than 5 mg/L (aOR, 34.378; 95% CI, 4.888-241.788; P < 0.001) was observed in patients with persistent infection.
EVAR is a feasible treatment with acceptable perioperative mortality for infected AAIA. Patients able to discontinue antibiotics have better survival and lower reintervention rates than those with persistent infection. A preoperative albumin level below 3 g/dL and primary aortoenteric fistula predicted persistent infection in this population.
感染性腹主动脉瘤和/或髂动脉瘤(IAIA)是一种罕见的疾病,采用开放手术治疗时死亡率很高。在过去十年中,这种疾病越来越多地采用血管内动脉瘤修复术(EVAR)治疗。然而,早期和晚期的结果,包括持续需要抗生素治疗和持续性感染的预测因素,仍了解甚少。
我们评估了 2010 年 1 月至 2017 年 10 月期间接受 EVAR 治疗的感染性 IAIA 患者的结果。我们收集了包括患者年龄、性别、临床表现、动脉瘤位置、培养结果、手术细节、术后并发症、30 天死亡率、住院死亡率、持续性感染、再次干预和生存等数据。
在 792 例诊断为 AAIA 的患者中,有 64 例被诊断为原发性感染性动脉瘤,接受了 EVAR,并纳入了本研究(81.3%为男性;中位年龄为 72 岁;范围为 18-94 岁)。最常见的分离菌是沙门氏菌(34%),其次是链球菌(21%)和葡萄球菌(21%)。48 例患者(75%)的动脉瘤完整,16 例(25%)的动脉瘤破裂。围手术期死亡率为 4.7%(3 例),其中 1 例被诊断为破裂性感染性 AAIA。6 例(9.4%)患者在住院期间死亡,5 例死于严重败血症合并多器官功能衰竭,1 例死于心肌梗死。在 58 例存活患者中,34 例(58.6%)存在持续性感染,其中 13 例(22.4%)需要早期和晚期再次干预,包括 2 例发生移植物感染,8 例发生原发性和继发性主动脉肠瘘,2 例发生复发性新主动脉感染,1 例发生移植物支闭塞。其余 24 例患者能够停用抗生素,无复发或需要再次干预。在抗生素停药组,1、3 和 5 年的总生存率分别为 91.7%、87.5%和 68.0%,持续性感染组分别为 82.4%、52.6%和 32.9%(P=0.009)。多变量分析显示,原发性主动脉肠瘘(调整后的比值比[aOR],20.469;95%置信区间[CI],1.265-331.320;P=0.034)和术前血清白蛋白水平<3g/dL(aOR,7.399;95%CI,1.176-46.558;P=0.033)是预测持续性感染的术前参数。持续性感染患者的 C 反应蛋白水平>5mg/L(aOR,34.378;95%CI,4.888-241.788;P<0.001)。
EVAR 是一种可行的治疗方法,对于感染性 AAIA 患者,其围手术期死亡率可接受。能够停用抗生素的患者比持续性感染的患者具有更好的生存和更低的再次干预率。术前白蛋白水平<3g/dL 和原发性主动脉肠瘘预测了该人群的持续性感染。